Point72 Asset Management L.P. Purchases 101,855 Shares of Aimmune Therapeutics, Inc. (AIMT)

Point72 Asset Management L.P. raised its position in Aimmune Therapeutics, Inc. (NASDAQ:AIMT) by 10.2% during the third quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 1,098,087 shares of the biotechnology company’s stock after purchasing an additional 101,855 shares during the quarter. Point72 Asset Management L.P. owned approximately 2.16% of Aimmune Therapeutics worth $27,222,000 at the end of the most recent quarter.

A number of other hedge funds and other institutional investors have also recently modified their holdings of the business. Vanguard Group Inc. grew its stake in Aimmune Therapeutics by 12.6% in the second quarter. Vanguard Group Inc. now owns 2,476,836 shares of the biotechnology company’s stock valued at $50,923,000 after purchasing an additional 276,978 shares in the last quarter. Eagle Asset Management Inc. lifted its position in shares of Aimmune Therapeutics by 6.3% in the second quarter. Eagle Asset Management Inc. now owns 2,270,160 shares of the biotechnology company’s stock worth $46,674,000 after buying an additional 135,374 shares during the last quarter. Palo Alto Investors LLC lifted its position in shares of Aimmune Therapeutics by 9.9% in the second quarter. Palo Alto Investors LLC now owns 1,289,719 shares of the biotechnology company’s stock worth $26,517,000 after buying an additional 116,221 shares during the last quarter. State Street Corp lifted its position in shares of Aimmune Therapeutics by 26.6% in the second quarter. State Street Corp now owns 1,087,320 shares of the biotechnology company’s stock worth $22,351,000 after buying an additional 228,429 shares during the last quarter. Finally, Citadel Advisors LLC lifted its position in shares of Aimmune Therapeutics by 3,092.5% in the third quarter. Citadel Advisors LLC now owns 559,641 shares of the biotechnology company’s stock worth $13,873,000 after buying an additional 542,111 shares during the last quarter. Hedge funds and other institutional investors own 73.34% of the company’s stock.

In related news, insider Susan E. Barrowcliffe sold 20,000 shares of the business’s stock in a transaction dated Monday, September 25th. The stock was sold at an average price of $25.00, for a total transaction of $500,000.00. Following the completion of the transaction, the insider now owns 20,000 shares of the company’s stock, valued at approximately $500,000. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. Also, CEO Stephen George Dilly sold 1,154 shares of the business’s stock in a transaction dated Monday, October 16th. The stock was sold at an average price of $26.24, for a total value of $30,280.96. The disclosure for this sale can be found here. Insiders have sold a total of 274,986 shares of company stock valued at $7,533,100 in the last three months. 17.59% of the stock is owned by insiders.

Shares of Aimmune Therapeutics, Inc. (NASDAQ:AIMT) opened at $33.60 on Wednesday. Aimmune Therapeutics, Inc. has a 12-month low of $15.97 and a 12-month high of $38.86.

Aimmune Therapeutics (NASDAQ:AIMT) last posted its quarterly earnings data on Monday, November 6th. The biotechnology company reported ($0.63) earnings per share for the quarter, topping the consensus estimate of ($0.72) by $0.09. research analysts anticipate that Aimmune Therapeutics, Inc. will post -2.54 EPS for the current fiscal year.

A number of analysts have weighed in on the company. Cantor Fitzgerald assumed coverage on Aimmune Therapeutics in a research report on Tuesday. They issued an “overweight” rating for the company. BidaskClub cut Aimmune Therapeutics from a “buy” rating to a “hold” rating in a research report on Saturday. Zacks Investment Research cut Aimmune Therapeutics from a “buy” rating to a “hold” rating in a research report on Wednesday, December 6th. Piper Jaffray Companies boosted their price target on Aimmune Therapeutics from $38.00 to $60.00 and gave the stock an “overweight” rating in a research report on Tuesday, December 5th. Finally, ValuEngine cut Aimmune Therapeutics from a “hold” rating to a “sell” rating in a research report on Friday, December 1st. One equities research analyst has rated the stock with a sell rating, two have given a hold rating and five have assigned a buy rating to the company’s stock. The company has an average rating of “Buy” and an average target price of $53.80.

ILLEGAL ACTIVITY WARNING: “Point72 Asset Management L.P. Purchases 101,855 Shares of Aimmune Therapeutics, Inc. (AIMT)” was first reported by The Ledger Gazette and is owned by of The Ledger Gazette. If you are accessing this report on another publication, it was copied illegally and reposted in violation of United States & international copyright law. The legal version of this report can be viewed at https://ledgergazette.com/2017/12/13/point72-asset-management-l-p-purchases-101855-shares-of-aimmune-therapeutics-inc-aimt.html.

About Aimmune Therapeutics

Aimmune Therapeutics, Inc is a clinical-stage biopharmaceutical company developing a therapeutic approach, including the development of product candidates, for the treatment of peanut and other food allergies. The Company’s therapeutic approach, which it refers to as Characterized Oral Desensitization Immunotherapy (CODIT), is a system designed to desensitize patients to food allergens using characterized biologic products, defined treatment protocols and support services.

Institutional Ownership by Quarter for Aimmune Therapeutics (NASDAQ:AIMT)

Receive News & Ratings for Aimmune Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Aimmune Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply